在软组织肉瘤中寻找新治疗途径的挑战。
The challenge of finding new therapeutic avenues in soft tissue sarcomas.
作者信息
Kasper Bernd
机构信息
Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.
出版信息
Clin Sarcoma Res. 2019 Apr 10;9:5. doi: 10.1186/s13569-019-0115-4. eCollection 2019.
Abstract
Soft tissue sarcomas are rare malignancies of mesenchymal origin comprising about 1% of all adult cancers. Systemic therapies for locally advanced and metastatic disease have been restricted for decades to very few effective and approved agents such as doxorubicin and ifosfamide. However, new therapeutic avenues including new drug developments and registrations such as trabectedin, pazopanib and eribulin as well as numerous clinical trial options have recently enriched the therapeutic armamentarium in the treatment of patients with advanced soft tissue sarcomas. The challenges and pitfalls of finding such new therapeutic avenues in recent years for the treatment benefit of patients with soft tissue sarcomas will be presented in this chapter within the thematic series on "Challenges in Sarcoma".
摘要
软组织肉瘤是一种罕见的间叶源性恶性肿瘤，约占所有成人癌症的1%。几十年来，针对局部晚期和转移性疾病的全身治疗一直局限于极少数有效的获批药物，如阿霉素和异环磷酰胺。然而，新的治疗途径，包括曲贝替定、帕唑帕尼和艾瑞布林等新药的研发和获批，以及众多临床试验选择，最近丰富了晚期软组织肉瘤患者治疗的武器库。本章将在“肉瘤治疗的挑战”这一主题系列中介绍近年来为软组织肉瘤患者寻求此类新治疗途径时所面临的挑战和陷阱。
相似文献
1
The challenge of finding new therapeutic avenues in soft tissue sarcomas.在软组织肉瘤中寻找新治疗途径的挑战。
Clin Sarcoma Res. 2019 Apr 10;9:5. doi: 10.1186/s13569-019-0115-4. eCollection 2019.
2
Optimal Prognostic Factors for Metastatic and Inoperable Sarcomas Treated With Pazopanib, Eribulin, and Trabectedin.帕唑帕尼、艾立布林和曲贝替定治疗转移性和不可手术肉瘤的最佳预后因素。
In Vivo. 2023 Nov-Dec;37(6):2634-2641. doi: 10.21873/invivo.13371.
3
Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options.晚期软组织肉瘤的治疗：多靶点药物曲贝替定的疗效与安全性，以及其他全身治疗选择的最新进展
Expert Rev Clin Pharmacol. 2016 Apr;9(4):501-512. doi: 10.1586/17512433.2016.1152179.
4
Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.曲贝替定在难治性软组织肉瘤治疗中作用的最新进展。
Onco Targets Ther. 2017 Feb 23;10:1155-1164. doi: 10.2147/OTT.S127955. eCollection 2017.
5
Trabectedin in soft tissue sarcomas.曲贝替定治疗软组织肉瘤
Mar Drugs. 2015 Feb 12;13(2):974-83. doi: 10.3390/md13020974.
6
[Histology-Specific Chemotherapy in Soft-Tissue Sarcomas].[软组织肉瘤的组织学特异性化疗]
Gan To Kagaku Ryoho. 2017 Jun;44(6):468-472.
7
The Role of Trabectedin in Soft Tissue Sarcoma.曲贝替定在软组织肉瘤中的作用。
Front Pharmacol. 2022 Feb 23;13:777872. doi: 10.3389/fphar.2022.777872. eCollection 2022.
8
Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.曲贝替定：海鞘素743、海鞘素 - 743、ET 743、ET - 743、NSC 684766。
Drugs R D. 2006;7(5):317-28. doi: 10.2165/00126839-200607050-00005.
9
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.软组织肉瘤的全身治疗：帕唑帕尼、曲贝替定和艾瑞布林最佳使用建议
Adv Ther. 2017 Jul;34(7):1556-1571. doi: 10.1007/s12325-017-0561-4. Epub 2017 May 25.
10
Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?使用外周免疫相关标志物能否指示晚期软组织肉瘤患者应使用帕唑帕尼、曲贝替定还是艾日布林？
J Clin Med. 2021 Oct 26;10(21):4972. doi: 10.3390/jcm10214972.
引用本文的文献
1
Efficacy of triplet antiemetic prophylaxis against chemotherapy-induced nausea and vomiting in patients with soft tissue sarcomas receiving consecutive-day doxorubicin and ifosfamide therapy.三联止吐预防方案对接受连续多日阿霉素和异环磷酰胺治疗的软组织肉瘤患者化疗所致恶心和呕吐的疗效。
Support Care Cancer. 2025 Mar 13;33(4):274. doi: 10.1007/s00520-025-09346-4.
2
Heterogeneity in response to neoadjuvant radiotherapy between soft tissue sarcoma histotypes: associations between radiology and pathology findings.软组织肉瘤组织学类型对新辅助放疗反应的异质性：放射学与病理学结果之间的关联
Eur Radiol. 2025 Mar;35(3):1337-1350. doi: 10.1007/s00330-024-11258-6. Epub 2024 Dec 19.
3
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.拉罗替尼在成人体细胞 Tropomyosin receptor kinase 融合肉瘤患者中的疗效和安全性。
Cancer. 2023 Dec 1;129(23):3772-3782. doi: 10.1002/cncr.35036. Epub 2023 Sep 28.
4
Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma.帕博利珠单抗联合奥拉单抗治疗不可切除、局部晚期或转移性软组织肉瘤的开放标签、Ib/IIa 期研究结果。
Clin Cancer Res. 2023 Sep 1;29(17):3320-3328. doi: 10.1158/1078-0432.CCR-23-0742.
5
Pan-sarcoma characterization of lncRNAs in the crosstalk of EMT and tumour immunity identifies distinct clinical outcomes and potential implications for immunotherapy.泛癌种长链非编码 RNA 特征分析 EMT 与肿瘤免疫的串扰，鉴定出不同的临床结局和对免疫治疗的潜在影响。
Cell Mol Life Sci. 2022 Jul 16;79(8):427. doi: 10.1007/s00018-022-04462-4.
本文引用的文献
1
An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial).TRC105 联合帕唑帕尼与帕唑帕尼单药治疗晚期血管肉瘤患者的适应性人群富集 III 期试验（TAPPAS 试验）。
Ann Oncol. 2019 Jan 1;30(1):103-108. doi: 10.1093/annonc/mdy464.
2
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.软组织和内脏肉瘤：ESMO-EURACAN诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269. doi: 10.1093/annonc/mdy321.
3
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.帕博利珠单抗治疗晚期软组织肉瘤和骨肉瘤（SARC028）：一项多中心、双队列、单臂、开放标签的2期试验。
Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4.
4
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.多柔比星联合依沃福酰胺与单纯多柔比星治疗局部晚期、不可切除或转移性软组织肉瘤（TH CR-406/SARC021）：一项国际多中心、开放标签的随机3期试验。
Lancet Oncol. 2017 Aug;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9. Epub 2017 Jun 23.
5
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.黑色素瘤与免疫疗法桥梁2015：意大利那不勒斯。2015年12月1日至5日。
J Transl Med. 2016 Jul 25;14(1):65. doi: 10.1186/s12967-016-0791-2.
6
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.塞利尼索（一种新型核输出抑制剂）用于晚期难治性骨或软组织肉瘤患者的1B期研究。
J Clin Oncol. 2016 Sep 10;34(26):3166-74. doi: 10.1200/JCO.2016.67.6346. Epub 2016 Jul 25.
7
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.奥拉单抗与多柔比星联合治疗与多柔比星单药治疗软组织肉瘤的疗效比较：一项开放标签的1b期和随机2期试验。
Lancet. 2016 Jul 30;388(10043):488-97. doi: 10.1016/S0140-6736(16)30587-6. Epub 2016 Jun 9.
8
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.帕博西尼治疗去分化或低分化脂肪肉瘤患者的无进展生存期：一项 2 期临床试验。
JAMA Oncol. 2016 Jul 1;2(7):937-40. doi: 10.1001/jamaoncol.2016.0264.
9
Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.XPO1抑制剂塞利尼索在肉瘤中的临床前活性。
Oncotarget. 2016 Mar 29;7(13):16581-92. doi: 10.18632/oncotarget.7667.
10
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.依立替康对比达卡巴嗪治疗既往治疗的晚期脂肪肉瘤或平滑肌肉瘤患者：一项随机、开放标签、多中心、III 期临床试验。
Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10.
Zotero 插件